Top News

On Tuesday, FDA Commissioner Marty Makary announced his resignation following increasing political pressure and internal disputes regarding his leadership. Reports indicate that President Donald Trump had been contemplating his removal for several months, particularly due to backlash from anti-abortion Republicans concerning his stance on the abortion pill mifepristone and its availability through telehealth.

In the wake of Makary's departure, Kyle Diamantas, a former FDA official, will step in as the acting head of the agency. Makary, who is also a surgeon at Johns Hopkins, led the FDA for 13 months, a period characterized by significant staff turnover, mass layoffs, and ongoing conflicts with lawmakers, pharmaceutical companies, and the White House.

Sources suggest that the decision to part ways with Makary had been in the works for some time. While the White House was reportedly on board with the decision, it was Health and Human Services Secretary Robert F. Kennedy Jr. who ultimately made the call.

Despite the swirling rumors about his future, Makary had public engagements lined up for the week and was still featured in agency press releases as late as Tuesday morning. Reports from FDA staff indicated that operations continued as usual, despite the uncertainty surrounding the commissioner's role.

Additionally, Makary faced challenges from Trump regarding flavored vape products after he initially raised concerns about them. Biopharmaceutical companies also expressed dissatisfaction with the FDA's performance under his leadership, claiming that the agency had become inconsistent in its drug review processes.

As the administration seeks a permanent replacement, Kyle Diamantas will oversee the FDA on an interim basis.